Business Daily Media

CD47 Monoclonal Antibody (AK117) Completed Phase I Dose Escalation Trial and Obtained Approval to Initiate Clinical Trial in Combination with Azacitidine for Treatment of Acute Myeloid Leukemia

  • Written by PR Newswire

HONG KONG, July 13, 2021 /PRNewswire/ -- Akeso, Inc. is pleased to announce that, CD47 monoclonal antibody (AK117), a second-generation novel drug for immuno-oncology therapy independently developed by the Company, has completed phase I dose escalation trial in Australia. AK117 resulted in no dose-limiting toxicity (DLT) and no anemia of clinical...

Why You Should Choose NetSuite to Improve Business Performance

Businesses that are serious about eliminating wasted time, money, and maximizing their ROI understand the value of streamlining their critical bus...

Business Training

Former Etihad boss brings substantial event insight to PMY Group Board

Paul Sergeant PMY Group, the architects of the digital insurgency occurring at major venues across Australia and New Zealand, are delighted to ...

Business Training

Mitigating Risk and Ensuring Compliance: The Benefits of Long-Term Disability Lawyers for Hamilton Businesses

Businesses in Hamilton face various challenges, and mitigating risk while ensuring compliance is crucial. Long-term disability lawyers play a key ...

Business Training

How to Effectively Use Seasonal Holidays to Boost Your Business’ Profits

Holiday periods can be a goldmine for the small business, if leveraged correctly. Here are four ways in which your small business can utilise seas...

Business Training

Funding-secured-for-new-Customer-Fulfilment-Centre

Australia’s leading online book retailer Booktopia Group Limited (ASX: BKG) (“the Company”) is  pleased to announce it has finalised a $12 million f...

Property

Leap Real Estate wins game-changing REA award

Resimax Group’s Leap Real Estate team has won Game Changer of the Year at the AREAs, the Annual REA Excellence Awards, for its world-first Leap Li...

Property